Screener
Rhythm Pharmaceuticals, Inc. RYTM Cash and cash equivalents, end of period
Cash and cash equivalents, end of period at other companies
Other financials
Where this comes from
Reported directly by Rhythm Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations.
The source filing: Rhythm Pharmaceuticals, Inc.’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-030549
| Line item | Three months ended March 31, 2026 | Three months ended March 31, 2025 |
|---|---|---|
| Proceeds from ATM equity offering | — | 34,034 |
| Net cash (used in) provided by financing activities | (5,400) | 32,499 |
| Effect of exchange rates on cash | 448 | (2) |
| Net increase in cash, cash equivalents and restricted cash | 7,915 | 16,958 |
| Cash, cash equivalents and restricted cash at beginning of period | 54,823 | 89,601 |
| Cash, cash equivalents and restricted cash at end of period | $62,738 | $106,559 |
| Supplemental disclosure of non-cash investing and financing activities: | ||
| Accretion of preferred stock dividends | $1,104 | $1,322 |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Rhythm Pharmaceuticals, Inc.'s cash and cash equivalents, end of period?
- Rhythm Pharmaceuticals, Inc. (RYTM) reported cash and cash equivalents, end of period of $62.74M in Q1 2026.
Ask your AI about Rhythm Pharmaceuticals, Inc.'s cash and cash equivalents, end of period.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude